The overall ratings of 22 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

United Therapeutics Corporation (UTHR) earns a D this week, moving down from last week’s grade of C. United Therapeutics Corporation is a biotechnology company that develops and commercializes therapeutic products for patients with chronic and life-threatening diseases. The company also gets F’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of UTHR stock.

This is a rough week for Intercept Pharmaceuticals, Inc. (ICPT). The company’s rating falls to F from the previous week’s D. The company also gets F’s in earnings revisions, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of ICPT stock.

This week, TESARO, Inc.’s (TSRO) rating worsens to a D from the company’s C rating a week ago. TESARO, Inc. develops and commercializes cancer therapeutics and supportive care products. The company also gets F’s in earnings momentum and return on equity. For more information, get Portfolio Grader’s complete analysis of TSRO stock.

Agios Pharmaceuticals, Inc. (AGIO) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in sales growth, earnings growth, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of AGIO stock.

AMAG Pharmaceuticals, Inc.’s (AMAG) rating weakens this week, dropping to a F versus last week’s D. AMAG Pharmaceuticals, Inc. utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The company also gets F’s in earnings growth, earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of AMAG stock.

This week, Coherus BioSciences, Inc. (CHRS) drops from a C to a D rating. Coherus BioSciences, Inc. focuses on developing and commercializing biosimilar products worldwide. The company also gets F’s in sales growth, earnings surprise, earnings momentum, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CHRS stock.

Insys Therapeutics, Inc. (INSY) experiences a ratings drop this week, going from last week’s C to a D. Insys Therapeutics, Inc. develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The company also gets F’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of INSY stock.

Insmed Incorporated (INSM) slips from a D to a F this week. Insmed Incorporated develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of INSM stock.

Slipping from a D to a F rating, OncoMed Pharmaceuticals, Inc. (OMED) takes a hit this week. The company also gets F’s in sales growth, earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of OMED stock.

Halozyme Therapeutics, Inc. (HALO) declines this week from a C to a D. Halozyme Therapeutics, Inc. is a biopharmaceutical company developing products for the diabetes, cancer, dermatology and drug delivery markets. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of HALO stock.

Flexion Therapeutics, Inc. (FLXN) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of FLXN stock.

Ardelyx, Inc. (ARDX) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in sales growth, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of ARDX stock.

Lion Biotechnologies, Inc. (LBIO) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of LBIO stock.

Slipping from a C to a D rating, Galmed Pharmaceuticals Ltd. (GLMD) takes a hit this week. The company also gets F’s in earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of GLMD stock.

ContraFect Corp. (CFRX) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CFRX stock.

This week, Chemocentryx, Inc.’s (CCXI) rating worsens to a F from the company’s D rating a week ago. Chemocentryx, Inc. a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CCXI stock.

Geron Corporation (GERN) declines this week from a C to a D. Geron Corporation is a biopharmaceutical company that discovers and develops therapeutic and diagnostic products to treat cancer and other age-related degenerative diseases including spinal cord injury, heart failure and diabetes. For more information, get Portfolio Grader’s complete analysis of GERN stock.

BioTime, Inc. (BTX) slips from a C to a D this week. BioTime, Inc. is a biotechnology company that focuses on regenerative medicine and blood plasma volume expanders. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of BTX stock.

Tonix Pharmaceuticals Holding Corp.’s (TNXP) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of TNXP stock.

This is a rough week for Pieris Pharmaceuticals, Inc. (PIRS). The company’s rating falls to D from the previous week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of PIRS stock.

This week, Amarin Corporation Plc Sponsored ADR (AMRN) drops from a B to a D rating. Amarin Corporation Plc Sponsored ADR focuses on developing the treatment for cardiovascular disease in the field of lipid science. The company also gets F’s in earnings surprise and free cash flow. For more information, get Portfolio Grader’s complete analysis of AMRN stock.

MEI Pharma, Inc. (MEIP) gets weaker ratings this week as last week’s D drops to a F. MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of MEIP stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.